logo-loader
Bushveld Minerals Limited

Bushveld Minerals says not aware of any corporate reason for share price fall, notes weakness in vanadium price

The AIM-listed group said, in spite of the price falls, it believes the vanadium market “remains in a structural deficit that will support higher prices in the medium to long term”

Vanadium
Bushveld also said it will be releasing a Mineral Resource and Ore Reserve update imminently

Bushveld Minerals Limited (LON:BMN) shares came off lows on Tuesday as the integrated primary vanadium producer said it was not aware of any corporate reason for a recent fall in its share price, although it highlighted weakness in the vanadium price.

In a statement commenting on the downward share price move, the AIM-listed group said, in spite of the price falls, it believes the vanadium market “remains in a structural deficit that will support higher prices in the medium to long term.”

READ: Bushveld Minerals signs off the first quarter on a high

The group also said it will be releasing a Mineral Resource and Ore Reserve update imminently.

In addition, the company said, its financial statements for the year ended 31 December 2018 are scheduled to be published within the current month.

In late morning trading, Bushveld shares were off 3.3% at 22.25p, but that was above the earlier session low of 19.50p.

Quick facts: Bushveld Minerals Limited

Price: £0.22

Market: LSE
Market Cap: £243.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Bushveld Minerals Limited named herein, including the promotion by the Company of Bushveld Minerals Limited in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: hVIVO’s mosquito vaccine moves into the clinic

Headlines from the Proactive Investors UK newsroom.  Clinical services group hVIVO’s (LON:HVO) experimental vaccine AGS-v PLUS is to undergo a phase 1 safety trial at the University of Maryland school of medicine. The vaccine is designed to protect against mosquito-borne diseases such as...

on 07/31/2019

2 min read